Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SHR-1501

Phase 2Small molecule

Shanghai Hengrui Pharmaceutical Co., Ltd.

1

Indications

4

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

NMIBCRecruiting

NMIBCPhase 2

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

NMIBC

NCT05410730

Q3 2030

Phase 3Recruiting

Non Muscle Invasive Bladder Cancer

NCT07726992

Clinical

Trials by Indication[1]

Advanced2 trials

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03995472·14 enrolled

A Study of SHR-1501 in Patients With Advanced Tumors

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04025957·19 enrolled

NMIBC1 trial

A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1/2·NCT05410730·150 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Multicenter, Randomized, Double-blind Phase III Study of Intravesical SHR-1501 Combined With Bacillus Calmette Guerin (BCG) Versus Placebo Combined With BCG In Patients With High-risk BCG-naive Papillary-Only Non-muscle-invasive Bladder Cancer (NMIBC)

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07726992·750 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SHR-1501. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-1501 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-1501. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Hengrui Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Shanghai Hengrui Pharmaceutical Co., Ltd.

Related News